Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

Alnylam Pharmaceuticals

6 Disclosed Funding Rounds $2,534,600,000

0 Participating Investments


Pharmaceutical, Therapeutics, Health Care, Biotechnology, Medical

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.

Cambridge, Massachusetts, United States, North America (US)

Organizations in Cambridge in Pharmaceutical,
Organizations in Cambridge in Therapeutics,
Organizations in Cambridge in Health Care,
Organizations in Cambridge in Biotechnology,
Organizations in Cambridge in Medical,
Organizations in Massachusetts in Pharmaceutical,
Organizations in Massachusetts in Therapeutics,
Organizations in Massachusetts in Health Care,
Organizations in Massachusetts in Biotechnology,
Organizations in Massachusetts in Medical,
Organizations in United States in Pharmaceutical,
Organizations in United States in Therapeutics,
Organizations in United States in Health Care,
Organizations in United States in Biotechnology,
Organizations in United States in Medical,
Organizations in North America in Pharmaceutical,
Organizations in North America in Therapeutics,
Organizations in North America in Health Care,
Organizations in North America in Biotechnology,
Organizations in North America in Medical

Investors in Cambridge in Pharmaceutical,
Investors in Cambridge in Therapeutics,
Investors in Cambridge in Health Care,
Investors in Cambridge in Biotechnology,
Investors in Cambridge in Medical,
Investors in Massachusetts in Pharmaceutical,
Investors in Massachusetts in Therapeutics,
Investors in Massachusetts in Health Care,
Investors in Massachusetts in Biotechnology,
Investors in Massachusetts in Medical,
Investors in United States in Pharmaceutical,
Investors in United States in Therapeutics,
Investors in United States in Health Care,
Investors in United States in Biotechnology,
Investors in United States in Medical,
Investors in North America in Pharmaceutical,
Investors in North America in Therapeutics,
Investors in North America in Health Care,
Investors in North America in Biotechnology,
Investors in North America in Medical

Greater Boston Area (0 Investors) (0 Startups), New England (0 Investors) (0 Startups), East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups)

Founded date 01, 2002

Founders Paul Schimmel, Phillip Sharp, Phillip D. Zamore, John Clarke, Thomas Tuschl, David Bartel, Robert Langer

Operating Status Active

Funding Stage IPO

Last Funding Type Post-IPO Debt

Also known as Alnylam

Company Type For Profit


Facebook Link

Twitter Link

LinkedIN Link

Wikipedia Link

Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Date Round Raised Lead
April, 13, 2020 Post-IPO Equity $250,000,000 Blackstone Life Sciences
April, 13, 2020 Post-IPO Debt $750,000,000 GSO Capital Partners
April, 08, 2019 Post-IPO Equity $800,000,000 Regeneron Pharmaceuticals
January, 13, 2014 Post-IPO Equity $700,000,000 Genzyme
March, 28, 2011 Post-IPO Equity $10,000,000 Takeda Pharmaceutical
July, 07, 2003 Venture - Series Unknown $24,600,000 -------

Alnylam Pharmaceuticals Investors (11)

Investor Lead? Round Participating Raise Date Partners
Blackstone Life Sciences Yes Post-IPO Equity $250,000,000 April, 13, 2020 -------
GSO Capital Partners Yes Post-IPO Debt $750,000,000 April, 13, 2020 -------
Regeneron Pharmaceuticals Yes Post-IPO Equity $800,000,000 April, 08, 2019 -------
Genzyme Yes Post-IPO Equity $700,000,000 January, 13, 2014 -------
Takeda Pharmaceutical Yes Post-IPO Equity $10,000,000 March, 28, 2011 -------
Atlas Venture No Venture - Series Unknown $24,600,000 July, 07, 2003 -------
ARCH Venture Partners No Venture - Series Unknown $24,600,000 July, 07, 2003 -------
Abingworth No Venture - Series Unknown $24,600,000 July, 07, 2003 -------
Cardinal Partners No Venture - Series Unknown $24,600,000 July, 07, 2003 -------
Merck No Venture - Series Unknown $24,600,000 July, 07, 2003 -------
Polaris Partners No Venture - Series Unknown $24,600,000 July, 07, 2003 -------